Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer

kamalabadi farahani, mohammad

doi:10.5505/tjo.2019.2179

Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer

Mohammad Kamalabadi FARAHANI (Tehran University of Medical Sciences, Faculty of Advanced Technologies in Medicine, Department of Tissue Engineering and Applied Cell Sciences, Tehran, Iran)

Türk Onkoloji Dergisi

3 0

Yıl: 2020 Cilt: 35 Sayı: 3 Sayfa Aralığı: 320 - 326 Metin Dili: İngilizce DOI: 10.5505/tjo.2019.2179 İndeks Tarihi: 26-11-2020

Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer

Öz:

OBJECTIVEMetastasis is a major cause of fatality in Triple-Negative Breast Cancer (TNBC). There is a significantcorrelation between metastasis and chemoresistance in cancers. Evasion during apoptosis, consideredas a hallmark of cancer, is a critical characteristic of metastatic tumor cells and the main cause of chemoresistance.In metastatic tumor cells, elucidating the mechanisms of apoptosis resistance is crucialto developing novel therapeutic strategies. In this study, we studied the expression of death receptors-5(DR-5) as an execution factor of apoptosis in the metastatic cascade of TNBC.METHODSUsing a 4T1 cell line, the animal model of metastatic breast cancer was made. Primary and metastatictumor cells were extracted from subcutaneous tumor and lung of cancerous mice, respectively. RealtimePCR was performed to analyze the level of DR-5 gene expression.RESULTSCell culture results demonstrated that metastatic tumor cells had comparatively greater proliferationpotential. Moreover, Real-time analysis indicated that DR-5 expression in metastatic tumor cells wassignificantly reduced.CONCLUSIONThese findings provide important insights regarding the molecular mechanism of apoptosis resistancephenomenon in metastatic tumor cells and can partly explain the reasons for the chemoresistance inmetastatic cells, which will highly likely to provide the basis for designing targeted therapeutic methodsto overcome chemoresistance and combat with metastatic TNBC.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017;8(1):1913–24.
2. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16(1):53–61.
3. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012;150(1):165–78.
4. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Breast Cancer Chemosensitivity. Springer; 2007. p. 1–22.
5. Wilson T, Johnston P, Longley D. Anti-apoptotic mechanisms of drug resistance in cancer. Current cancer drug targets 2009;9(3):307–19.
6. Yang L. Mechanisms of Apoptosis Resistance In Breast Cancer. In: Piccart HM, Solin LJ, Cardoso F, Wood WC, editors. Breast Cancer and Molecular Medicine. Berlin, Heidelberg: Springer: 2006. p. 841–58.
7. Martin SJ, Green DR. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol 1995;18(2):137–53.
8. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nature Reviews Cancer 2002;2(4):277.
9. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001;3(6):535– 46.
10. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275–92.
11. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, et al. A microRNA DNA methylation signature for human cancer metastasis. Version 2. Proc Natl Acad Sci U S A 2008;105(36):13556–61.
12. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009;136(4):586–91.
13. Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC, et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer research 2000;60(9):2541–6.
14. Prasad S, Kim JH, Gupta SC, Aggarwal BB. Targeting death receptors for TRAIL by agents designed by Mother Nature. Trends Pharmacol Sci 2014;35(10):520–36.
15. Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL, et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol 2013;9(2):84–9.
16. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24(36):5652–7.
17. Davuluri G, Schiemann WP, Plow EF, Sossey-Alaoui K. Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1α-mediated angiogenesis. JAKSTAT 2015;3(4):e1009276.
18. Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003;9(9):3397–405.
19. Macher-Goeppinger S, Aulmann S, Tagscherer KE, Wagener N, Haferkamp A, Penzel R, et al. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin Cancer Res 2009;15(2):650–9.
20. Ganten TM, Sykora J, Koschny R, Batke E, Aulmann S, Mansmann U, et al. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) 2009;87(10):995–1007.
21. Uddin S, Hussain AR, Ahmed M, Al-Sanea N, Abduljabbar A, Ashari LH, et al. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma. Am J Pathol 2011;179(6):3032– 44.
22. Li Y, Jin X, Li J, Jin X, Yu J, Sun X, et al. Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis. Urology 2012;79(4):968.e7–15.
23. Duiker EW, van der Zee AG, de Graeff P, Boersmavan Ek W, Hollema H, de Bock GH, et al. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol 2010;116(3):549–55.
24. Maduro JH, Noordhuis MG, ten Hoor KA, Pras E, Arts HJ, Eijsink JJ, et al. The prognostic value of TRAIL and its death receptors in cervical cancer. Int J Radiat Oncol Biol Phys 2009 1;75(1):203–11.
25. Oh YT, Yue P, Wang D, Tong JS, Chen ZG, Khuri FR, et al. Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling. Oncotarget 2015;6(38):41324–38.
26. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001;61(13):4942–6.
27. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 1999;59(22):5683–6.
28. Pai SI, Wu GS, Ozören N, Wu L, Jen J, Sidransky D, El- Deiry WS. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998;58(16):3513–8.
29. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin’s lymphoma. Oncogene 2001;20(3):399–403.
30. Park WS, Lee JH, Shin MS, Park JY, Kim HS, Kim YS, et al. Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology 2001;121(5):1219– 25.
31. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. Version 2. J Clin Invest 2008;118(1):100–10.
32. Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008;118(1):111–23.
33. Malin D, Chen F, Schiller C, Koblinski J, Cryns VL. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer. Clin Cancer Res 2011;17(15):5005–15.

APA	kamalabadi farahani m (2020). Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer. , 320 - 326. 10.5505/tjo.2019.2179
Chicago	kamalabadi farahani mohammad Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer. (2020): 320 - 326. 10.5505/tjo.2019.2179
MLA	kamalabadi farahani mohammad Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer. , 2020, ss.320 - 326. 10.5505/tjo.2019.2179
AMA	kamalabadi farahani m Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer. . 2020; 320 - 326. 10.5505/tjo.2019.2179
Vancouver	kamalabadi farahani m Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer. . 2020; 320 - 326. 10.5505/tjo.2019.2179
IEEE	kamalabadi farahani m "Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer." , ss.320 - 326, 2020. 10.5505/tjo.2019.2179
ISNAD	kamalabadi farahani, mohammad. "Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer". (2020), 320-326. https://doi.org/10.5505/tjo.2019.2179

APA	kamalabadi farahani m (2020). Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer. Türk Onkoloji Dergisi, 35(3), 320 - 326. 10.5505/tjo.2019.2179
Chicago	kamalabadi farahani mohammad Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer. Türk Onkoloji Dergisi 35, no.3 (2020): 320 - 326. 10.5505/tjo.2019.2179
MLA	kamalabadi farahani mohammad Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer. Türk Onkoloji Dergisi, vol.35, no.3, 2020, ss.320 - 326. 10.5505/tjo.2019.2179
AMA	kamalabadi farahani m Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer. Türk Onkoloji Dergisi. 2020; 35(3): 320 - 326. 10.5505/tjo.2019.2179
Vancouver	kamalabadi farahani m Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer. Türk Onkoloji Dergisi. 2020; 35(3): 320 - 326. 10.5505/tjo.2019.2179
IEEE	kamalabadi farahani m "Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer." Türk Onkoloji Dergisi, 35, ss.320 - 326, 2020. 10.5505/tjo.2019.2179
ISNAD	kamalabadi farahani, mohammad. "Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer". Türk Onkoloji Dergisi 35/3 (2020), 320-326. https://doi.org/10.5505/tjo.2019.2179